About Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, and norovirus. We have reported favorable safety and tolerability results from a Phase 1 clinical trial targeting pandemic and seasonal influenza A and plan to begin a Phase 2a human challenge trial in the second half of 2023, and we plan to begin a Phase 1 trial with an oral antiviral candidate for SARS-CoV-2 in the first half of 2023.